Characteristics of FLT3-ITD at diagnosis between patients treated with midostaurin that were FLT3-ITD positive vs negative at the time of disease progression
| Variable . | Patients treated with midostaurin (n = 54) . | P . | |
|---|---|---|---|
| FLT3-ITD positive at disease progression (n = 29) . | FLT3-ITD negative at disease progression (n = 25) . | ||
| Pts with multiple ITDs, n (%) | 10 (34) | 5 (20) | .36 |
| Total number of ITDs, n | 43 | 31 | ND |
| FLT3-ITD AR | |||
| Median (range) | 0.62 (0.10-4.32) | 0.39 (0.06-0.96) | .03 |
| FLT3-ITD nt length | |||
| Median (range) | 57 (18-225) | 51 (21-198) | .69 |
| FLT3-ITD insertion sites, n (%) | .63 | ||
| JMD | 27 (63) | 17 (55) | |
| JM-Z | 17 (40) | 12 (39) | |
| JM-S | 1 (2) | 1 (3) | |
| Hinge region | 9 (21) | 4 (13) | |
| TKD1 | 16 (37) | 14 (45) | |
| Beta1-sheet | 15 (35) | 14 (45) | |
| Nucleotide binding loop | 1 (2) | 0 (0) | |
| Variable . | Patients treated with midostaurin (n = 54) . | P . | |
|---|---|---|---|
| FLT3-ITD positive at disease progression (n = 29) . | FLT3-ITD negative at disease progression (n = 25) . | ||
| Pts with multiple ITDs, n (%) | 10 (34) | 5 (20) | .36 |
| Total number of ITDs, n | 43 | 31 | ND |
| FLT3-ITD AR | |||
| Median (range) | 0.62 (0.10-4.32) | 0.39 (0.06-0.96) | .03 |
| FLT3-ITD nt length | |||
| Median (range) | 57 (18-225) | 51 (21-198) | .69 |
| FLT3-ITD insertion sites, n (%) | .63 | ||
| JMD | 27 (63) | 17 (55) | |
| JM-Z | 17 (40) | 12 (39) | |
| JM-S | 1 (2) | 1 (3) | |
| Hinge region | 9 (21) | 4 (13) | |
| TKD1 | 16 (37) | 14 (45) | |
| Beta1-sheet | 15 (35) | 14 (45) | |
| Nucleotide binding loop | 1 (2) | 0 (0) | |
JMD, juxtamembrane domain; NA, not available; ND, not determined; nt, nucleotide.